Harpula
Steve Powell has a diverse work experience spanning several companies in the pharmaceutical and healthcare industry. Steve has held various executive roles and has been involved in strategic planning, business development, and operational management. Steve's most recent role was as the CEO and Founding Partner of Harpula, and prior to that, they served as a Board Member at Assentia, Inc. Steve also held the position of Chief Executive Officer at Synteract, where they played a key role in the company's growth and successful acquisition by Syneos Health. Steve has also worked at ERT, Exco InTouch, PRA Health Sciences, Datatrial, AVOS Life Sciences, and INC Research, where they held positions of executive leadership and was responsible for various aspects of business operations and development.
Steve Powell attended Aberdare Boys Comprehensive School from 1980 to 1987 where they did not earn a degree or specialize in any particular field of study. After completing their schooling at Aberdare, they pursued higher education at Cardiff University / Prifysgol Caerdydd from 1987 to 1990. At Cardiff University, they obtained a Bachelor of Science (B.Sc.) degree in Mathematics & Biostatistics.
This person is not in any teams
This person is not in any offices
Harpula
Harpula was formed to foster the growth of next generation technology and services for clinical trials. Our goal is to build a company that excels in today’s clinical trial landscape of personalized medicine, multiple trial modalities, and increased patient centricity. Harpula builds on the founders’ years of experience in clinical trial execution and technology. We recognize the opportunity to build a more coordinated technology solution through acquisition and organic growth. We seek to invest in companies and assets in the technology-enabled pharmaceutical solutions industry to improve the clinical trial experience for patients, sites, and sponsors. Technology solutions have had a tremendously positive impact on the quality and efficiency of clinical trials. As the number and type of solutions have propagated, the burden on sponsors, sites, and patients has increased. There is opportunity to consolidate platforms to address critical pain points around the patient and site experience and ultimately deliver drugs to patients faster.